David E Leaf1, Mohan Rajapurkar2, Suhas S Lele3, Banibrata Mukhopadhyay2, Sushrut S Waikar4. 1. Division of Renal Medicine, Brigham and Women's Hospital, Boston, Massachusetts; and DELEAF@partners.org. 2. Department of Nephrology. 3. Department of Cardiology, Muljibhai Patel Urological Hospital, Gujarat, India. 4. Division of Renal Medicine, Brigham and Women's Hospital, Boston, Massachusetts; and.
Abstract
BACKGROUND AND OBJECTIVES: Catalytic iron has been hypothesized to be a key mediator of AKI. However, the association between plasma catalytic iron levels and AKI has not been well studied in humans. DESIGN, SETTINGS, PARTICIPANTS, & MEASUREMENTS: A single-center, prospective, nonconsecutive cohort study of 121 critically ill patients admitted to intensive care units (ICUs) between 2008 and 2012 was performed. Plasma catalytic iron, free hemoglobin, and other iron markers were measured on ICU days 1 and 4. The primary end point was in-hospital mortality or AKI requiring RRT. Secondary end points included mortality (assessed during hospitalization, at 30 days, and 1 year) and incident AKI, defined by modified Kidney Disease Improving Global Outcomes criteria. RESULTS: ICU day 1 plasma catalytic iron levels were higher among patients who reached the primary end point (median, 0.74 µmol/l [interquartile range, 0.31-3.65] versus 0.29 µmol/l [0.22-0.46]; P<0.01). ICU day 1 plasma catalytic iron levels were associated with number of packed red blood cell transfusions before ICU arrival (rs=0.29; P<0.001) and plasma free hemoglobin levels on ICU day 1 (rs=0.32; P<0.001). Plasma catalytic iron levels on ICU day 1 were significantly associated with in-hospital mortality or AKI requiring RRT, even after adjusting for age, enrollment eGFR, and number of packed red blood cell transfusions before ICU arrival (13 events; adjusted odds ratio per 1-SD higher ln[catalytic iron], 3.33; 95% confidence interval, 1.79 to 6.20). ICU day 1 plasma catalytic iron levels were also significantly associated with incident AKI, RRT, hospital mortality, and 30-day mortality. CONCLUSIONS: Among critically ill patients, elevated plasma catalytic iron levels on arrival to the ICU are associated with a greater risk of incident AKI, RRT, and hospital mortality.
BACKGROUND AND OBJECTIVES: Catalytic iron has been hypothesized to be a key mediator of AKI. However, the association between plasma catalytic iron levels and AKI has not been well studied in humans. DESIGN, SETTINGS, PARTICIPANTS, & MEASUREMENTS: A single-center, prospective, nonconsecutive cohort study of 121 critically ill patients admitted to intensive care units (ICUs) between 2008 and 2012 was performed. Plasma catalytic iron, free hemoglobin, and other iron markers were measured on ICU days 1 and 4. The primary end point was in-hospital mortality or AKI requiring RRT. Secondary end points included mortality (assessed during hospitalization, at 30 days, and 1 year) and incident AKI, defined by modified Kidney Disease Improving Global Outcomes criteria. RESULTS: ICU day 1 plasma catalytic iron levels were higher among patients who reached the primary end point (median, 0.74 µmol/l [interquartile range, 0.31-3.65] versus 0.29 µmol/l [0.22-0.46]; P<0.01). ICU day 1 plasma catalytic iron levels were associated with number of packed red blood cell transfusions before ICU arrival (rs=0.29; P<0.001) and plasma free hemoglobin levels on ICU day 1 (rs=0.32; P<0.001). Plasma catalytic iron levels on ICU day 1 were significantly associated with in-hospital mortality or AKI requiring RRT, even after adjusting for age, enrollment eGFR, and number of packed red blood cell transfusions before ICU arrival (13 events; adjusted odds ratio per 1-SD higher ln[catalytic iron], 3.33; 95% confidence interval, 1.79 to 6.20). ICU day 1 plasma catalytic iron levels were also significantly associated with incident AKI, RRT, hospital mortality, and 30-day mortality. CONCLUSIONS: Among critically ill patients, elevated plasma catalytic iron levels on arrival to the ICU are associated with a greater risk of incident AKI, RRT, and hospital mortality.
Authors: Sean M Bagshaw; Garth Mortis; Christopher J Doig; Tomas Godinez-Luna; Gordon H Fick; Kevin B Laupland Journal: Am J Kidney Dis Date: 2006-09 Impact factor: 8.860
Authors: John R Prowle; Vaughn Ostland; Paolo Calzavacca; Elisa Licari; E Valentina Ligabo; Jorge E Echeverri; Sean M Bagshaw; Anja Haase-Fielitz; Michael Haase; Mark Westerman; Rinaldo Bellomo Journal: Nephrol Dial Transplant Date: 2011-07-29 Impact factor: 5.992
Authors: A K Jacob; R S Hotchkiss; S L DeMeester; M Hiramatsu; I E Karl; P E Swanson; J P Cobb; T G Buchman Journal: Surgery Date: 1997-08 Impact factor: 3.982
Authors: M M Rajapurkar; S S Lele; T S Malavade; M R Kansara; U N Hegde; K D Gohel; S D Gang; S V Shah; B N Mukhopadhyay Journal: Indian J Nephrol Date: 2013-09
Authors: David E Leaf; Mohan Rajapurkar; Suhas S Lele; Banibrata Mukhopadhyay; Emily A S Boerger; Finnian R Mc Causland; Michele F Eisenga; Karandeep Singh; Jodie L Babitt; John A Kellum; Paul M Palevsky; Marta Christov; Sushrut S Waikar Journal: J Am Soc Nephrol Date: 2019-02-08 Impact factor: 10.121
Authors: Rupal C Mehta; Monique E Cho; Xuan Cai; Jungwha Lee; Jing Chen; Jiang He; John Flack; Tariq Shafi; Santosh L Saraf; Valentin David; Harold I Feldman; Tamara Isakova; Myles Wolf Journal: Kidney Int Date: 2021-07-30 Impact factor: 10.612